Digital Trials Digest, our quarterly newsletter
A quarterly look at what's new in ObvioGo, where decentralized trials are heading, and the partnerships shaping what's next — new Image Capture & Central Rating features, caregiver-collected growth data research, and what's coming in OG-2.10.
Issue 2: new Assent & Countersignature capabilities, ObvioGo's direct integration with Oracle Health and Life Sciences, Novotech's multi-trial licensing agreement, and SCOPE 2026 takeaways.
Issue 1: ObvioGo's new built-in eSignature, the Template Library and Out-of-Window Data Submissions features, caregiver-centric eDiary design, and how MiHelper accelerated a decentralized migraine study.
We know that a patient-centric approach to clinical trials generally leads to higher compliance and retention rates. DCTs are more convenient for participants.
In the first of our two-part series exploring minority participation in clinical trial research, we examine the numerous challenges to securing diversity in clinical trials and the consequences of primarily white patient populations.
ObvioHealth tackles misconceptions about decentralized clinical trials, they’re less safe, they’re always fully virtual, the data isn’t trustworthy, and so on.
BYOD ePRO models deliver a range of benefits to clinical trial stakeholders, including increased engagement, reduced site team burden, and more.
Digital therapeutics are playing an increasing role in mental health care. Ensuring that these DTx products meet quality thresholds is key to effective care.